Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume 9, Issue 3, Pages 355-365Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17512433.2016.1133285
Keywords
refractory; salvage line; metastatic colorectal cancer; TAS-102; phase III; intolerant; chemotherapy
Categories
Funding
- Taiho Pharmaceutical Co., Ltd.
Ask authors/readers for more resources
TAS-102 is a new oral anti-tumor drug, composed of a thymidine-based nucleoside analog (trifluridine: FTD) and a thymidine phosphorylase inhibitor (tipiracil hydrochloride: TPI). TAS-102 has been shown to significantly improve overall survival and progression-free survival in patients with refractory metastatic colorectal cancer (mCRC) in placebo-controlled randomized phase II and III trials. The current review summarizes mechanisms of action, pharmacokinetics/dynamics and preclinical and clinical data of TAS-102 in colorectal cancer. TAS-102 is a new salvage-line treatment option for patients with mCRC. TAS-102 is well tolerated and has great potential in future clinical drug combination therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available